Deferoxamine

In some countries, this medicine may only be approved for veterinary use.

In the US, Deferoxamine (deferoxamine systemic) is a member of the following drug classes: antidotes, chelating agents and is used to treat Iron Poisoning - Acute and Iron Poisoning - Chronic.

US matches:

• Deferoxamine


• Deferoxamine Injection


• Deferoxamine Mesylate

Scheme

Prop.INN

ATC (Anatomical Therapeutic Chemical Classification)

V03AC01

CAS registry number (Chemical Abstracts Service)

0000070-51-9

Chemical Formula

C25-H48-N6-O8

Molecular Weight

560

Therapeutic Category

Antidote: Chelating agent

Chemical Name

Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-

Foreign Names

• Deferoxaminum (Latin)
• Deferoxamin (German)
• Déferoxamine (French)
• Deferoxamina (Spanish)

Generic Names

• Deferoxamina (OS: DCIT)
• Deferoxamine (OS: USAN)
• Déféroxamine (OS: DCF)
• Desferrioxamine (OS: BAN)
• Desferrin (IS)
• Desferroxiamin B (IS)
• DFOA (IS)
• Deferoxamine Hydrochloride (OS: USAN)
• Ba 29837 (IS)
• Deferoxamine Mesilate (OS: JAN)
• Deferoxamine Mesylate (OS: USAN)
• Desferrioxamine Mesilate (OS: BANM)
• Ba 33112 (IS)
• Deferoxamine methanesulfonate (IS)
• Desferrioxamine Mesilate (IS)
• DFOM (IS)
• Déféroxamine (mésilate de) (PH: Ph. Eur. 6)
• Deferoxamine Mesilate (PH: Ph. Eur. 6, Ph. Int. 4, JP XV)
• Deferoxamine Mesylate (PH: USP 32)
• Deferoxamini mesilas (PH: Ph. Int. 4, Ph. Eur. 6)
• Deferoxaminmesilat (PH: Ph. Eur. 6)
• Desferrioxamine Mesilate (PH: BP 2010)

Brand Names

• Desferal
  Novartis, Ghana; Novartis, Guyana; Novartis, India; Novartis, Kenya; Novartis, Libya; Novartis, Nigeria; Novartis, Russian Federation; Novartis, Sudan; Novartis, Turkey; Novartis, Tanzania; Novartis, Zimbabwe



• Desféral
  Novartis, Tunisia



• Deferoxamine mesylate
  APP, United States



• Desferal
  Novartis, Czech Republic



• Deferoxamine mesylate
  Bedford, United States; Hospira, United States; Teva USA, United States; Watson, United States



• Deferoxamine-Teva
  Biogal, Israel



• Desferal
  EU-Pharma, Netherlands; Euro, Netherlands; Novartis, Argentina; Novartis, Austria; Novartis, Australia; Novartis, Belgium; Novartis, Bulgaria; Novartis, Bahrain; Novartis, Brazil; Novartis, Canada; Novartis, Switzerland; Novartis, Chile; Novartis, China; Novartis, Colombia; Novartis, Germany; Novartis, Denmark; Novartis, Finland; Novartis, United Kingdom; Novartis, Greece; Novartis, Hong Kong; Novartis, Hungary; Novartis, Indonesia; Novartis, Ireland; Novartis, Israel; Novartis, Italy; Novartis, Japan; Novartis, Sri Lanka; Novartis, Luxembourg; Novartis, Malta; Novartis, Malaysia; Novartis, Netherlands; Novartis, Norway; Novartis, Oman; Novartis, Philippines; Novartis, Poland; Novartis, Portugal; Novartis, Romania; Novartis, Sweden; Novartis, Slovakia; Novartis, Thailand; Novartis, Taiwan; Novartis, United States; Novartis, Vietnam; Novartis, South Africa



• Desféral
  Novartis, France



• Desferal (veterinary use)
  Novartis Animal Health, United Kingdom



• Desferin
  Novartis, Spain



• Desferrioxamine Mesilate
  Hospira, Canada



• Desferrioxamine Mesylate DBL
  Hospira, Australia; Hospira, New Zealand; Hospira, Singapore; Mayne, Hong Kong



• Talifer
  Lemery, Sri Lanka

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Prop.INN	Proposed International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.